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Abstract 6
7
Ras/Raf/MEK/ERK(Ras-ERK) signaling has been implicated in the effects of drugs of abuse. 8
Inhibitors of MEK1/2, the kinases upstream of ERK1/2, have been critical in defining the role 9
of the Ras-ERK cascade in drug-dependent alterations in behavioral plasticity, but the Ras 10
family of small GTPases has not been extensively examined in drug-related behaviors. We 11
examined the role of Ras Guanine Nucleotide Releasing Factor 1(RasGRF1) and 12
2(RasGRF2), upstream regulators of the Ras-ERK signaling cascade, on cocaine self-13
administration(SA) in male mice. We first established a role for Ras-ERK signaling in 14
cocaine SA, demonstrating that pERK1/2 is upregulated following SA in C57Bl/6N mice in 15
striatum. We then compared RasGRF1 and RasGRF2 knock-out(KO) mouse lines, 16
demonstrating that cocaine SA in RasGRF2 KO mice was increased relative to wild-17
type(WT) controls, while RasGRF1 KO and WT mice did not differ. This effect in RasGRF2 18
mice is likely mediated by the Ras-ERK signaling pathway, as pERK1/2 upregulation 19
following cocaine SA was absent in RasGRF2 KO mice. Interestingly, the lentiviral 20
knockdown of RasGRF2 in the NAc had the opposite effect to that in RasGRF2 KO mice, 21
reducing cocaine SA. We subsequently demonstrated that the MEK inhibitor PD325901 22
administered peripherally prior to cocaine SA increased cocaine intake, replicating the 23
increase seen in RasGRF2 KO mice, while PD325901 administered into the NAc decreased 24
cocaine intake, similar to the effect seen following lentiviral knockdown of RasGRF2. These 25
data indicate a role for RasGRF2 in cocaine SA in mice that is ERK-dependent, and suggest a 26
differential effect of global versus site-specific RasGRF2 inhibition.27
28
29
30
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SIGNIFICANCE STATEMENT  31
Exposure to drugs of abuse activates a variety of intracellular pathways, and following 32
repeated exposure, persistent changes in these pathways contribute to drug dependence. 33
Downstream components of the Ras-ERK signaling cascade are involved in the acute and 34
chronic effects of drugs of abuse, but their upstream mediators have not been extensively 35
characterized. Here we show using a combination of molecular, pharmacological, and 36
lentiviral techniques that the guanine nucleotide exchange factor RasGRF2 mediates cocaine 37
self-administration via an ERK-dependent mechanism, while RasGRF1 has no effect on 38
responding for cocaine. These data indicate dissociative effects of mediators of Ras activity 39
on cocaine reward and expands the understanding of the contribution of Ras-ERK signaling to 40
drug-taking behavior.  41
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Introduction 56
57
58
The extracellular signal-regulated kinases (ERK) cascade (Ras/Raf/MEK/ERK; Ras-ERK) 59
couples activity at cell surface receptors with the activation of transcription factors and 60
subsequent gene expression (Grewal et al., 1999; Mazzucchelli and Brambilla, 2000). Largely61
known for its regulation of cell proliferation, differentiation and survival (Roberts and Der, 62
2007; Mandala et al., 2014), the Ras-ERK pathway also plays a critical role in long-term 63
potentiation and memory formation (Brambilla et al., 1997; Jin and Feig, 2010), as well as64
reinforcement and enduring drug-dependent plasticity (Valjent et al., 2000; Ferguson et al., 65
2006; Girault et al., 2007). Indeed, this pathway has been implicated in the acute and chronic 66
effects of a variety of drugs of abuse, most notably cocaine and other psychostimulants 67
(Valjent et al., 2000; Lu et al., 2005; Miller and Marshall, 2005). 68
69
The majority of studies defining the role of the Ras-ERK pathway in drug-mediated behaviors 70
have been achieved using inhibitors of MEK1/2, the kinases upstream of ERK1/2, while the 71
Ras family of small GTPases has not been extensively examined. Ras family GTPases link 72
extracellular signals to distinct intracellular signaling cascades by switching from an inactive 73
GDP-bound state to an active GTP-bound state, each of which recognizes a distinct set of 74
effector proteins and thereby allows Ras to function as a molecular switch (Takai et al., 2001; 75
Cox and Der, 2010). The activation state of Ras proteins is controlled by two types of 76
regulatory proteins. Guanine nucleotide exchange factors (GEFs) catalyze the release of 77
bound GDP, thus allowing activating GTP to replace it. GTPase activating proteins (GAPs) 78
promote the ability of Ras to hydrolyze GTP to GDP (Boguski and McCormick, 1993; 79
Pamonsinlapatham et al., 2009). Multiple mammalian families of GEFs regulate the Ras 80
activation cycle (Cox and Der, 2010). Particularly important with respect to the Ras-ERK 81
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pathway in neuronal signaling are two members of the Ras guanine nucleotide releasing factor 82
(RasGRF) family of GEFs, RasGRF1 and RasGRF2, that allow certain neurotransmitter 83
receptors to activate Ras in a Ca2+/calmodulin-dependent manner (Farnsworth et al., 1995). 84
85
RasGRF1 has been shown to play a role in the neuronal and behavioral responses to both 86
psychostimulants and alcohol (Zhang et al., 2007; Fasano et al., 2009; Parelkar et al., 2009; 87
Ben Hamida et al., 2012). For example, RasGRF1 KO mice show a decrease in the 88
phosphorylation of ERK (pERK) in the ventral striatum in response to cocaine, while 89
RasGRF1 overexpressing mice show an increased pERK in the ventral striatum following 90
cocaine, as well as decreased and increased, respectively, cocaine-mediated locomotor 91
sensitization and conditioned place preference (Fasano et al., 2009). The extent to which 92
RasGRF2 may be involved in drug-mediated behaviors has to date been primarily restricted to 93
alcohol studies. A single-nucleotide polymorphism in the gene encoding RasGRF2 has been 94
associated with alcohol consumption (Schumann et al., 2011) and further linked to alcohol-95
related reward anticipation (Stacey et al., 2012) and binge drinking in male adolescents 96
(Stacey et al., 2016), and RasGRF2 KO mice demonstrated a loss in alcohol-induced 97
dopamine increase in the nucleus accumbens (NAc) and reduction in alcohol drinking (Stacey 98
et al., 2012). However, it is unclear whether the involvement of RasGRF2 extends to other 99
drugs of abuse. 100
101
The purpose here was to better characterize the role of the Ras-ERK pathway by direct 102
comparison of the contribution of RasGRF1 and RasGRF2 to cocaine-mediated behaviors.103
We first established a role for the Ras-ERK pathway in cocaine SA by performing 104
immunohistochemistry for pERK1/2, as well as the phosphorylation of (Ser10)-acetylated 105
(Lys14) histone H3 (pAcH3), a nuclear ERK substrate that has demonstrated involvement in 106
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drug-induced neuroadaptations in both rodents and humans (Brami-Cherrier et al., 2009; 107
Damez-Werno et al., 2016; Papale et al., 2016). We then performed SA in RasGRF1 and 108
RasGRF2 KO mice and WT littermate controls, followed by further pERK and pAcH3 109
analysis. We also performed site-specific lentiviral knockdown of RasGRF1 and RasGRF2 in 110
mice in the NAc, as well as in the dorsal striatum (DS). Finally, we examined the effects of 111
both the peripheral and site-specific inhibition of MEK1/2 on cocaine SA. Our experiments 112
indicate a role for RasGRF2, but not RasGRF1, in cocaine SA in mice.113
114
Material and Methods 115
116
Animals 117
118
C57Bl/6N mice (Charles River, Germany) and male RasGRF1 (Brambilla et al., 1997) and 119
RasGRF2 (Fernandez-Medarde et al., 2002) KO mice and their WT littermate controls were 120
single-housed in a temperature-controlled (21 °C) environment maintained on a 12-hr light-121
dark cycle (lights on at 6 a.m.). Food and water was available ad libitum. All experiments 122
were performed in accordance with EU guidelines on the care and use of laboratory animals123
and were approved by the local animal care committee. All behavioral testing was conducted 124
during the light phase between 0800 h and 1700 h.125
126
Drugs 127
128
Cocaine hydrochloride (Sigma-Aldrich, Germany) was dissolved in physiological saline 129
(0.9% NaCl) for 0.50 mg/kg/14 µl infusion for SA (Bernardi et al., 2017). PD325901 (Sigma-130
Aldrich, Germany) was dissolved in 100% dimethyl sulfoxide (DMSO) and diluted to a 20% 131
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DMSO solution with sterile 0.9% NaCl for IP injection of 10 mg/kg (10 ml/kg). For 132
intracranial administration, PD325901 (Carbosynth Limited, UK) was dissolved in 100% 133
dimethyl sulfoxide (DMSO) and diluted to a 0.002% DMSO solution with sterile 0.9% NaCl134
for intracranial injection of 5 ng/0.5 µl/side. This dose was determined using a comparison of 135
its IC50 to that of other MEK inhibitors commonly used for intracranial injection. The vehicle 136
for all PD325901 experiments consisted of an identical % DMSO solution as that used for the 137
drug.138
139
Lentiviral vector production 140
The LV-RasGRF1-shRNA, LV-RasGRF2-shRNA and LV-scrambled-shRNA were 141
constructed and prepared as previously described (Bido et al., 2015). Briefly, expression 142
plasmids for Ras-GRF1 and Ras-GRF2 RNA interference were obtained from a commercial 143
source (OriGene, Rockville, MD). The following sequences were used as shRNA inserts 144
against RasGRF1 and RasGRF2, respectively: 145
GACGGCCTGGTCAACTTCTCCAAGATGAG and 146
TAATGCAGAAGTACATTCATCTAGTTCAG. The company provided all scrambled 147
control sequences. The shRNA gene specific expression cassettes (U6-shRNA cassette) were 148
cloned into the pCCLsin.PPT.hPGK.eGFP.PRE lentiviral construct. VSV-pseudotyped third-149
generation lentiviral vectors (LV) were produced as previously described (Indrigo et al., 2010; 150
Papale and Brambilla, 2014). Western blots demonstrating knockdown of both RasGRF1 and 151
RasGRF2 proteins both in vitro and in vivo in striatal cells have been shown previously (Bido 152
et al., 2015).153
154
Apparatus & Procedures 155
156
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Cocaine SA   157
Cocaine SA was assessed in 12 operant chambers (Med Associates, USA) housed in light- 158
and sound-attenuating cubicles.  Each chamber (24.1 x 20.3 x 18.4 cm) is equipped with two 159
levers (left and right), a food dispenser and a drug delivery system connected via infusion 160
pump (PHM-100, Med-Associates, USA) located outside the cubicle. Operant chambers were 161
controlled using Med-PC IV (Med Associates, USA) software.  Mice first underwent lever 162
training with 14 mg sweetened food pellets (TestDiet, USA), as previously described 163
(Bernardi and Spanagel, 2013). Following lever training, mice were implanted with an 164
indwelling intravenous catheter (made in-house) into the jugular vein. Catheter patency was 165
maintained with 0.15 ml heparanized saline (100 i.u./ml) containing Baytril (0.7 mg/ml) 166
administered daily throughout the experiment.  After 3d recovery, mice underwent daily 1hr 167
cocaine SA for 7 consecutive days.  Cocaine (0.50 mg/kg/14 µl infusion) delivery was 168
contingent upon pressing on the active lever under an FR2 schedule of reinforcement (unless 169
otherwise specified) and paired with the 20s presentation of a blinking light stimulus 170
(Conditioned Stimulus, CS), which also served as a timeout period, during which lever 171
presses were not reinforced.  For all experiments, presses on the inactive lever were recorded 172
but had no scheduled consequence. 173
174
Immunohistochemistry 175
Immunohistochemistry was performed following the protocol described in Papale et al, 2016. 176
Free-floating sections were rinsed in TBS and then incubated for 15 min in a quenching 177
solution containing 3% H2O2 and 10% methanol. One hour after blocking in 5% normal goat 178
serum and 0.1% Triton X-100, sections were incubated overnight at 4°C with anti-phospho-179
p44/42 MAP kinase (Thr202/Tyr204) (1:1000, Cell Signaling Technology Cat# 4370L, 180
RRID:AB_231511), anti-phospho (Ser10)-acetylated (Lys14) histone H3 (1:500, Millipore 181
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Cat# 07–081, RRID:AB_310366), or anti-GFP antibody (1:500, Life Technologies Cat# 182
A11122, RRID: AB_221569). The next day, slices were rinsed in TBS and incubated with 183
biotinylated goat anti-rabbit IgG (1:200, Vector Laboratories Cat# BA-1000, 184
RRID:AB_2313606) for 2 hours at room temperature. Detection of the bound antibodies was 185
carried out using a standard peroxidase-based method (ABC-kit, Vectastain, Vector Labs), 186
followed by incubation with DAB and H2O2 solution. Images were acquired from the dorsal 187
and ventral striatum with a bright field microscope (Leica DM2000LED Macro/micro 188
imaging system) at 20X magnification. Neuronal quantification was carried out using ImageJ 189
software. The total number of pERK1/2- and pAcH3-positive cells was counted in the dorsal 190
and ventral striatum in 2 consecutive rostral sections per mouse.191
192
Lentivirus microinjections 193
Mice were anesthetized by isoflurane (4% for induction, 1% for maintenance), secured in a 194
stereotaxic frame (David Kopf Instruments, Tujunga, USA), and the lentiviral vectors (LV-195
RasGRF1-shRNA, LV-RasGRF2-shRNA and LV-scrambled-shRNA) were bilaterally 196
injected into the NAc (AP +1.20; ML +/-0.90; DV -4.75, relative to Bregma) or DS (AP 197
+0.00; ML +/-2.20; DV -3.30, relative to Bregma) in a volume of 0.5 µl/hemisphere over 2 198
min (at a rate of 0.125 µl/min). After the infusion, needles were left in place for additional 2 199
min to allow for diffusion. Mice were then sutured and allowed to recover from surgical 200
procedures. After the completion of behavioral experiments, mice were anesthesized with 201
isoflurane and perfused with 5 ml ice-cold phosphate-buffered saline (PBS) and 5 ml 4% 202
paraformaldehyde (PFA) in PBS; their brains were removed and kept in 4% PFA in PBS over 203
night for post-fixation, and then transferred into 30% sucrose in PBS solution for at least 24 204
hours. Coronal sections (30 µm) were subsequently taken at the level of the NAc or DS with a 205
cryostat (Leica Microsystems, Wetzlar, Germany), mounted onto polarized glass slides and 206
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eGFP expression was imaged using fluorescent microscopy. The extension of virus spread 207
was assessed manually based on the mouse brain atlas (Paxinos and Franklin, 2004). Animals 208
with placements outside of the NAc or DS, with unilateral expression or extensive mechanical 209
damage were excluded. It must be noted here that no distinction was made between core and 210
shell or dorsolateral and dorsomedial striatum in terms of virus injections, due to the difficulty 211
in targeting one region specifically in mice.212
213
Cannula implantation and microinjections 214
Following food training, mice were anesthetized by isoflurane (4% for induction, 1% for 215
maintenance), secured in a stereotaxic frame (David Kopf Instruments, USA), and cannula 216
(Plastics One, USA) were mounted above the NAc (C235GS, double cannula, AP +1.20; ML 217
+/-0.75; DV -2.75, relative to Bregma) or DS (C315GS, bilateral single cannula, AP +0.00; 218
ML +/-2.20; DV -1.80, relative to Bregma) secured using screws and dental cement and 219
dummy cannulae (C235DCS and C315DCS for NAc and DS, respectively, Plastics One, 220
USA) were inserted to protect the cannulae. Mice were then allowed to recover from surgical 221
procedures for 7 days. Dummy cannulae were removed prior to and replaced following daily 222
SA sessions to habituate the animals to the handling procedure. Microinjections of PD325901 223
were conducted using internal cannula (C235IS and C315IS for NAc and DS, respectively, 224
Plastics One, USA) that extended beyond the cannula guide (2 mm for NAc and 1.5 mm for 225
DS) in a volume of 0.5 µl/hemisphere over 2 min (at a rate of 0.125 µl/min) under isoflurane 226
anesthesia. After the infusion, needles were left in place for additional 2 min to allow for 227
diffusion. After the completion of behavioral experiments, all mice were anesthesized with 228
isoflurane, cannulae were injected with coomassie blue dye, and brains were removed and 229
flash-frozen in isopentane for placement verification. Coronal sections (30 µm) were assessed 230
as to cannula placement using the mouse brain atlas (Paxinos and Franklin, 2004). Animals 231
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with placements outside of the NAc or DS were excluded. It must be noted here that no 232
distinction was made between core and shell or dorsolateral and dorsomedial striatum in terms 233
of intracranial injections, due to the difficulty in targeting one region specifically in mice.234
235
Experimental design and statistical analysis 236
237
Statistical analyses were conducted using SPSS software (StatSoft, USA). All SA data was 238
performed using three-way [number of presses: genotype/treatment (between subjects) x lever 239
(within subjects) x day (within subjects)] or two-way ANOVAs [number of reinforcers: 240
genotype/treatment (between subjects) x day (within subjects)], followed by Bonferroni-241
corrected independent samples t-tests, where indicated. Cocaine intake data following 242
intracranial PD325901 microinjection was compared using independent samples t-tests, where 243
indicated. Immunohistochemical data in RasGRF2 KO mice and controls were conducted 244
using a two-way ANOVA [genotype (between subjects) x treatment (between subjects)], 245
followed by independent samples t-tests, where indicated. Immunohistochemical data in all 246
other experiments were compared using independent samples t-tests, except where data was 247
non-normal, in which a Mann-Whitney U-Test was used (where indicated). Significance was 248
set at p < .05.249
250
Results 251
252
pERK1/2 and pAcH3 are increased in C57Bl/6N mice following cocaine SA253
We previously showed that acute cocaine resulted in an increase in the number of pERK1/2- 254
and pAcH3-positive cells in the ventral and dorsal striatum (Papale et al, 2016). Here we 255
sought to determine the role of the Ras-ERK pathway in cocaine SA using these indicators. 256
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We first performed immunochemistry for pERK1/2- and pAcH3-positive cells in the ventral 257
and dorsal striatum on the 7th day of SA. C57Bl/6N mice underwent cocaine (n = 5) or saline 258
(n = 6) SA (as described above), with animals sacrificed 30 min following the first infusion 259
achieved on day 7. Following testing, mice were anesthesized with isoflurane and 260
transcardially perfused with phosphate-buffered saline (PBS) and 4% paraformaldehyde 261
(PFA) in PBS. Brains were removed and placed in 4% PFA in PBS for 24h for post-fixation, 262
and then transferred into 20% sucrose in PBS for at least 24h and finally into 30% sucrose in 263
PBS until processing.   264
265
pERK1/2 analysis  266
Following cocaine SA, C57Bl/6N mice demonstrated an increase in the number of pERK1/2-267
positive cells in response to cocaine on day 7 relative to saline controls in both the ventral and 268
dorsal striatum. Figure 1A shows the mean number of pERK1/2-positive cells (± SEM) in the 269
ventral striatum following cocaine or saline SA in C57Bl/6N mice. A Mann-Whitney U-Test 270
revealed that distributions of the number of pERK1/2-positive cells in the ventral striatum in 271
animals that underwent cocaine and saline SA differed significantly [U < .0005, Z = -2.7, p = 272
.004]. Figure 1B shows the mean number of pERK1/2-positive cells (± SEM) in the dorsal 273
striatum following cocaine or saline SA in C57Bl/6N mice.  An independent samples t-test 274
revealed that animals that underwent cocaine SA demonstrated a significant increase in the 275
number of pERK1/2-positive cells in the dorsal striatum relative to saline controls [t(4.6) = 276
4.8, p = .006]. Figure 1C shows representative slices of pERK1/2-positive cells from the 277
ventral and dorsal striatum of C57Bl6N mice that underwent cocaine or saline SA.278
279
pAcH3 analysis  280
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Following cocaine SA, C57Bl/6N mice demonstrated an increase in the number of pAcH3-281
positive cells in response to cocaine on day 7 relative to saline controls in both the ventral and 282
dorsal striatum.  Figure 1D shows the mean number of pAcH3-positive cells (± SEM) in the 283
ventral striatum following cocaine or saline SA in C57Bl/6N mice.  An independent samples 284
t-test revealed that animals that underwent cocaine SA demonstrated a significant increase in 285
the number of pAcH3-positive cells in the ventral striatum relative to saline controls [t(5.0) = 286
5.3, p = .003]. Figure 1E shows the mean number of pAcH3-positive cells (± SEM) in the 287
dorsal striatum following cocaine or saline SA in C57Bl/6N mice.  An independent samples t-288
test revealed that animals that underwent cocaine SA demonstrated a significant increase in 289
the number of pAcH3-positive cells in the dorsal striatum relative to saline controls [t(9) = 290
5.0, p = .001]. Figure 1F shows representative slices of pAcH3-positive cells from the ventral 291
and dorsal striatum of C57Bl6N mice that underwent cocaine or saline SA. 292
293
These data suggest that pERK1/2 and pAcH3 are increased as a result of cocaine SA mice, 294
suggesting that these downstream components of the Ras-ERK pathway may be critical for 295
cocaine reward. 296
297
Cocaine SA was increased in RasGRF2 KO mice, but unaffected in RasGRF1 mice  298
To determine the contribution of RasGRF1 and RasGRF2 to cocaine SA, RasGRF1 and 299
RasGRF2 KO lines were used. These lines have been previously demonstrated to show 300
impaired cocaine-related behaviors and alcohol intake, respectively (Fasano et al., 2009; 301
Stacey et al., 2012). RasGRF1 KO mice (n = 11) and WT littermate controls (n = 10), and 302
RasGRF2 KO mice (n = 19) and WT littermate controls (n = 14), underwent SA for 7d as 303
described above.  304
305
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RasGRF1 KO mice and WT controls did not differ in cocaine SA. Figure 2A shows the mean 306
(± SEM) responding on the active and inactive levers during 7 daily 1hr sessions of cocaine 307
SA in RasGRF1 KO mice and WT controls.  A three-way ANOVA (lever x day x genotype) 308
revealed significant main effects of lever [F(1,19) = 51.8, p < .0005], indicating a distinction 309
between the active and inactive levers, and day [F(2.1,39.1) = 4.8, p = .024], but no other 310
significant effects [Fs < 1], indicating no difference in lever responding between KO and WT 311
mice. Figure 2B shows the mean (± SEM) number of cocaine infusions received during 7d of 312
cocaine SA in RasGRF1 KO mice and WT controls.  A two-way ANOVA (day x genotype) 313
revealed no significant effects of genotype [Fs < 1], indicating no difference in cocaine intake 314
in RasGRF1 KO mice relative to WT controls.  315
316
RasGRF2 KO mice and WT controls differed in cocaine SA, with RasGRF2 KO mice 317
demonstrating an increase in responding on the cocaine-associated lever and subsequent318
cocaine intake. Figure 2C shows the mean (± SEM) responding on the active and inactive 319
levers during 7 daily 1hr sessions of cocaine SA in RasGRF2 KO mice and WT controls.  A 320
three-way ANOVA (lever x day x genotype) revealed significant main effects of lever 321
[F(1,31) = 201.5, p < .0005], indicating a distinction between the active and inactive levers, 322
and a significant main effect of genotype [F(1,31) = 12.8, p = .001], and importantly, a lever x 323
genotype interaction [F(1,31) = 6.3, p = .017], indicating a difference between KO and WT 324
controls over 7d of cocaine SA. No other effects reached significance [Fs < 1, except lever x 325
day: F(2.4,74.4) = 2.4, p = .088]. Independent samples t-tests confirmed that RasGRF2 KO 326
mice responded more on the active lever than control mice [t(31) = 3.6, p = .001; Bonferroni-327
corrected α = .025] across days, but the two groups did not differ on inactive lever pressing 328
[t(31) = 1.6, p = .119; Bonferroni-corrected α = .025], indicating a selective increase in 329
responding on the cocaine-associated lever by RasGRF2 KO mice relative to littermate 330
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controls.  Figure 2D shows the mean (± SEM) number of cocaine infusions received during 331
7d of cocaine SA in RasGRF2 KO mice and WT controls.  A two-way ANOVA (day x 332
genotype) revealed a significant main effect of genotype [F(1,31) = 9.0, p = .005], but no 333
other significant effects [day: F(2.9,91.0) = 1.1, p = .363; day x genotype: F(2.9,91.0) = 1.9, p 334
= .142], indicating an increase in cocaine intake in RasGRF2 KO mice relative WT controls.335
336
These findings suggest that RasGRF2, but not RasGRF1, is important in mediating cocaine 337
reward in mice during SA.  Because previous studies have demonstrated a decrease in alcohol 338
reward in RasGRF2 KO mice (Stacey et al., 2012), these data also suggest that RasGRF2 KO 339
results in a decrease in putative cocaine reward that in terms of IV SA is compensated for by 340
an increase in intake.341
342
pERK1/2 and pAcH3 are inhibited in RasGRF2 KO mice following cocaine SA 343
As RasGRF2 KO in mice altered cocaine SA, immunohistochemical analyses were performed 344
to determine whether RasGRF2 KO affected pERK1/2- and pAcH3 activation during cocaine 345
SA, which we showed above likely mediates cocaine reward. The numbers of pERK1/2- and 346
pAcH3-positive cells were measured in the ventral and dorsal striatum of RasGRF2 KO mice 347
and WT littermate controls on the 7th day of SA.  RasGRF2 KO (cocaine, n = 4; saline, n = 5) 348
and WT controls (cocaine, n = 4; saline, n = 5) underwent cocaine or saline SA as described 349
above, with animals sacrificed 30 min following the first reinforcer achieved on day 7. 350
Following testing, mice were anesthesized with isoflurane and transcardially perfused with 351
phosphate-buffered saline (PBS) and 4% paraformaldehyde (PFA) in PBS. Brains were 352
removed and placed in 4% PFA in PBS for 24h for post-fixation, and then transferred into 353
20% sucrose in PBS for at least 24h and finally into 30% sucrose in PBS until processing.  354
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355
pERK1/2 analysis  356
Following cocaine SA, WT mice of the RasGRF2 line demonstrated an increase in the 357
number of pERK1/2-positive cells in response to cocaine on day 7 relative to saline controls 358
in both the ventral and dorsal striatum, consistent with the data from C57Bl/6N mice shown in 359
Figure 1. The increase in the number of pERK1/2-positive cells on day 7 was not present in 360
either the ventral or dorsal striatum of RasGRF2 KO mice. Figure 3A shows the mean number 361
of pERK1/2-positive cells (± SEM) in the ventral striatum in RasGRF2 KO mice and WT 362
controls that were sacrificed on day 7 after cocaine or saline SA. A two-way ANOVA 363
(genotype x treatment) of the number of pERK1/2-positive cells revealed significant main 364
effects of genotype [F(1,14) = 8.2, p = .012] and treatment [F(1,14) = 6.6, p < .022], and a 365
significant genotype x treatment interaction [F(1,14) = 7.0, p = .019]. An independent samples 366
t-test revealed an attenuation of the number of pERK1/2-positive cells in RasGRF2 KO mice 367
that underwent cocaine SA, relative to WT controls [t(6) = 2.9, p = .027]. Figure 3B shows 368
the mean number of pERK1/2-positive cells (± SEM) in the dorsal striatum in RasGRF2 KO 369
mice and WT controls that were sacrificed on day 7 after cocaine or saline SA. A two-way 370
ANOVA (genotype x treatment) of the number of pERK1/2-positive cells revealed significant 371
main effects of genotype [F(1,14) = 18.8, p = .001] and treatment [F(1,14) = 34.0, p < .0005], 372
and a significant genotype x treatment interaction [F(1,14) = 13.3, p = .003]. An independent 373
samples t-test revealed an attenuation of the number of pERK1/2-positive cells in RasGRF2 374
KO mice that underwent cocaine SA, relative to WT controls [t(6) = 3.6, p = .011]. Figure 3C 375
shows representative slices of pERK-positive cells from the ventral and dorsal striatum of 376
RasGRF2 KO mice and WT controls that underwent cocaine or saline SA. 377
378
pAcH3 analysis  379
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Following cocaine SA, WT mice of the RasGRF2 line demonstrated an increase in the 380
number of pAcH3-positive cells in response to cocaine on day 7 relative to saline controls in 381
both the ventral and dorsal striatum, consistent with the data from C57Bl/6N mice shown in 382
Figure 1. The increase in the number of pAcH3-positive cells on day 7 was not present in 383
either the ventral or dorsal striatum of RasGRF2 KO mice. Figure 3D shows the mean number 384
of pAcH3-positive cells (± SEM) in the ventral striatum in RasGRF2 KO mice and WT 385
controls that were sacrificed on day 7 after cocaine or saline SA. A two-way ANOVA 386
(genotype x treatment) of the number of pAcH3-positive cells revealed significant main 387
effects of genotype [F(1,14) = 7.9, p = .014] and treatment [F(1,14) = 22.3, p < .0005], and a 388
significant genotype x treatment interaction [F(1,14) = 14.8, p = .002]. An independent 389
samples t-test revealed an attenuation of the number of pAcH3-positive cells in RasGRF2 KO 390
mice that underwent cocaine SA, relative to littermate controls [t(6) = 3.3, p = .017]. Figure 391
3E shows the mean number of pAcH3-positive cells (± SEM) in the dorsal striatum in 392
RasGRF2 KO mice and littermate controls that were sacrificed on day 7 after cocaine or 393
saline SA. A two-way ANOVA (genotype x treatment) of the number of pAcH3-positive cells 394
revealed significant main effects of genotype [F(1,14) = 7.4, p = .017] and treatment [F(1,14) 395
= 6.0, p = .028], and a significant genotype x treatment interaction [F(1,14) = 11.8, p = .004]. 396
An independent samples t-test revealed an attenuation of the number of pAcH3-positive cells 397
in RasGRF2 KO mice that underwent cocaine SA, relative to littermate controls [t(6) = 3.2, p 398
= .019]. Figure 3F shows representative slices of pAcH3-positive cells from the ventral and 399
dorsal striatum of RasGRF2 KO mice and WT controls that underwent cocaine or saline SA. 400
401
These data suggest that RasGRF2 mediates cocaine reward through an ERK-dependent 402
pathway. Furthermore, these data are supportive of the hypothesis that the increase in SA 403
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demonstrated in RasGRF2 KO mice results from an inhibition of pERK-mediated reward and 404
a consequent compensatory increase in cocaine intake.405
406
Lentiviral-mediated knockdown of RasGRF2 into the NAc and DS decreased cocaine 407
intake408
Here we sought to determine the contribution of RasGRF2 specifically in the NAc on cocaine 409
SA in mice using lentiviral-mediated knockdown of RasGRF2. Because RasGRF1 KO mice 410
showed no difference in cocaine SA as compared to littermate wild-type controls, we used 411
lentiviral-mediated knockdown of RasGRF1 in the NAc as a control. Four weeks following 412
microinjections of LV-RasGRF2-shRNA (n = 9) or LV-scrambled-shRNA (n = 11), or LV-413
RasGRF1-shRNA (n = 12) or LV-scrambled-shRNA (n = 13), into the NAc, mice underwent414
7d of cocaine SA as described above. In a separate experiment, we further determined 415
whether microinjections of LV-RasGRF2-shRNA into the DS affected cocaine SA in mice. 416
Four weeks following microinjections of LV-RasGRF2-shRNA (n = 9) or LV-scrambled-417
shRNA (n = 6) into the DS, C57Bl/6N mice underwent 7d of cocaine SA as described above. 418
Mice from this DS group were sacrificed immediately after the final SA session on day 7 so 419
that in addition to virus and placement verification, alterations in pERK activity during 420
cocaine SA using immunohistochemistry could also be assessed.421
422
Microinjections of LV-RasGRF2-shRNA into the NAc resulted in a decrease in cocaine 423
intake during SA, relative to LV-scrambled-shRNA controls. Figures 4A and 4B show 424
representative viral eGFP expression images using fluorescent microscopy and DAB staining, 425
respectively, of the LV-RasGRF2-shRNA and LV-scrambled-shRNA constructs for the NAc. 426
Figure 4C shows the mean (± SEM) responding on the active and inactive levers during 7 427
daily 1hr days of cocaine SA following NAc microinjection of LV-RasGRF2-shRNA and 428
19 
LV-scrambled-shRNA constructs. A three-way ANOVA (lever x day x treatment) revealed a 429
significant main effect of lever [F(1,18) = 61.4, p < .0005], indicating a distinction between 430
the active and inactive levers, but no other significant effects [Fs < 1, except lever x 431
treatment: F(1,18) = 1.5, p = .238; lever x day: F(6,108) = 2.1, p = .063; lever x day x 432
treatment: F(6,108) = 1.3, p = .267; treatment: F(1,18) = 2.5, p = .132], indicating no 433
significant difference in active lever-specific responding as a function of treatment. Figure 4D 434
shows the mean (± SEM) number of cocaine infusions received during 7d of cocaine SA. A 435
two-way ANOVA (day x treatment) indicated a main effect of treatment [F(1,18) = 4.8, p = 436
.043], but no other significant effects [Fs < 1], indicating a decrease in cocaine intake 437
resulting from the LV-RasGRF2-shRNA microinjection. 438
439
Microinjections of LV-RasGRF1-shRNA into the NAc did not affect cocaine SA, relative to 440
LV-scrambled-shRNA controls.  Figures 5A and 5B show representative viral eGFP 441
expression images using fluorescent microscopy and DAB staining, respectively, of the LV-442
RasGRF1-shRNA and LV-scrambled-shRNA constructs for the NAc.  Figure 5C shows the 443
mean (± SEM) responding on the active and inactive levers during 7 daily 1hr days of cocaine 444
SA following NAc microinjection of LV-RasGRF1-shRNA and LV-scrambled-shRNA 445
constructs. A three-way ANOVA (lever x day x treatment) revealed significant main effects 446
of lever [F(1,23) = 86.8, p < .0005], indicating a distinction between the active and inactive 447
levers, and a lever x day interaction [F(3.8,87.2) = 3.0, p = .032], but no other significant 448
effects [Fs < 1], indicating no difference in lever responding as a function of treatment.  449
Figure 5D shows the mean (± SEM) number of cocaine infusions received during 7d of 450
cocaine SA following NAc microinjection of LV-RasGRF1-shRNA and LV-scrambled-451
shRNA constructs.  A two-way ANOVA (day x treatment) revealed no significant effects [Fs 452
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< 1], indicating no difference in cocaine intake resulting from LV-RasGRF1-shRNA 453
treatment relative to the scrambled control.454
455
Microinjections of LV-RasGRF2-shRNA into the DS resulted in a decrease in cocaine intake 456
during SA, relative to LV-scrambled-shRNA controls.  Figures 6A and 6B show 457
representative viral eGFP expression images using fluorescent microscopy and DAB staining, 458
respectively, of the LV-RasGRF2-shRNA and LV-scrambled-shRNA constructs for the DS.  459
Figure 6C shows the mean (± SEM) responding on the active and inactive levers during 7 460
daily 1hr days of cocaine SA following DS microinjection of LV-RasGRF2-shRNA and LV-461
scrambled-shRNA constructs. A three-way ANOVA (lever x day x treatment) revealed 462
significant main effects of lever [F(1,13) = 104.0, p < .0005], indicating a distinction between 463
the active and inactive levers, a main effect of treatment [F(1,13) = 6.6, p = .023], a lever x 464
day interaction [F(1.9,24.6) = 7.0, p = .004], and only a trend toward a lever x treatment 465
interaction [F(1,13) = 4.5, p = .054], but no other significant effects [day: F(2.6,33.9) = 2.2, p 466
= .110; day x treatment: F(2.6,33.9) = 1.5, p = .233; lever x day x treatment: F(1.9,24.6) = 2.3, 467
p = .128], indicating no significant difference in active lever-specific responding as a function 468
of treatment.  Figure 6D shows the mean (± SEM) number of cocaine infusions received 469
during 7d of cocaine SA following DS microinjection of LV-RasGRF2-shRNA and LV-470
scrambled-shRNA constructs.  A two-way ANOVA (day x treatment) revealed a main effect 471
of treatment [F(1,13) = 10.7, p = .006], but no other significant effects [Fs < 1, except day: 472
F(2.4,31.0) = 1.4, p = .258], indicating a decrease in cocaine intake resulting from the LV-473
RasGRF2-shRNA microinjection.474
475
Immediately following the final session of cocaine SA, LV-RasGRF2-shRNA mice 476
demonstrated a decrease in the number of pERK1/2-positive cells in response relative to LV-477
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scrambled-shRNA controls in the dorsal striatum. Figure 7 shows the mean number of 478
pERK1/2-positive cells (± SEM) in the dorsal striatum in LV-RasGRF2-shRNA and LV-479
scrambled-shRNA mice that were sacrificed on day 7 after cocaine SA, as well as 480
representative slices of pERK-positive cells from the dorsal striatum of these groups An 481
independent samples t-test revealed a decrease in the number of pERK1/2-positive cells in 482
LV-RasGRF2-shRNA mice that underwent cocaine SA, relative to LV-scrambled-shRNA483
controls [t(13) = 6.3, p < .0005]. These data are representative of the ability of LV-RasGRF2-484
shRNA to inhibit Ras-ERK signaling in striatal tissue as measured by pERK activation.485
486
These data confirm a role for RasGRF2 in the NAc, as well as in the DS, in cocaine SA in 487
mice. Because LV-RasGRF2-shRNA reduced cocaine intake, in contrast to the increase in 488
intake demonstrated in RasGRF2 KO mice, further examination is required.489
490
Peripheral  PD325901 increased, while intra-NAc PD325901 decreased, cocaine SA in 491
mice. 492
As our results above show, there were opposing results on cocaine intake in RasGRF2 KO 493
mice (increased) and animals administered LV-RasGRF2-shRNA (decreased). We sought to 494
clarify this inconsistency using the selective MEK inhibitor PD325901 administered both 495
peripherally and site-specifically during cocaine SA.  We previously showed that PD325901 496
crosses the blood brain barrier and inhibits the increased pERK1/2 and pAcH3 associated with 497
acute cocaine (Papale et al, 2016). For peripheral PD325901 administration, C57Bl/6N mice 498
underwent 7d of cocaine SA under an FR1 schedule of reinforcement following pretreatment 499
with vehicle (n = 9) or PD325901 (10 mg/kg; n = 11) 30 min prior to the start of each daily 500
session.  For immunohistochemical confirmation of the effect of PD325901 on pERK1/2 501
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signaling, a separate group of C57Bl/6N mice underwent 7d of cocaine SA under an FR2 502
schedule of reinforcement following pretreatment with vehicle (n = 5) or PD325901 (10 503
mg/kg; n = 5) 30 min prior to the start of each daily session, with animals sacrificed 30 min 504
following the first infusion achieved on day 7. For intracranial injection, mice implanted with 505
cannulae aimed at either the NAc (vehicle, n = 10; PD325901, n = 9) or DS (vehicle, n = 6; 506
PD325901, n = 7) underwent 7d of cocaine SA under an FR2 schedule of reinforcement.507
PD325901 was injected 30 min prior to the cocaine SA session on day 7, and mice were given 508
additional SA sessions on days 8 and 9.509
510
Vehicle- and PD325901-administered mice differed in cocaine intake following peripheral 511
administration. Figure 8A shows the mean (± SEM) responding on the active and inactive 512
levers during 7 daily 1hr sessions of cocaine SA following IP administration of PD325901 or 513
vehicle. A three-way ANOVA (lever x day x treatment) revealed a significant main effect of 514
lever [F(1,18) = 62.4, p < .0005], indicating a distinction between the active and inactive 515
levers, a significant lever x day interaction [F(3.3,59.1) = 4.0, p = .01], and a main effect of 516
treatment [F(1,18) = 4.9, p = .04], but no other significant effects [Fs < 1, except lever x 517
treatment: F(1,18) = 3.0, p = .10; day x treatment: F(3.0,54.7) = 1.4, p = .249]. Figure 8B 518
shows the mean (± SEM) number of cocaine infusions received during 7d of cocaine SA 519
following IP administration of PD325901 or vehicle. A two-way ANOVA (treatment x day) 520
revealed significant main effects of treatment [F(1,18) = 15.8, p = .001] and day [F(3.0,54.4) 521
= 3.4, p = .024], and a significant treatment x day interaction [F(3.0,54.4) = 3.9, p = .013]. 522
523
PD325901-treated C57Bl/6N mice demonstrated a decrease in the number of pERK1/2-524
positive cells in response to cocaine on day 7 relative to vehicle-treated mice in both the 525
ventral and dorsal striatum. Figure 8C shows the mean number of pERK1/2-positive cells (± 526
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SEM) in the ventral striatum on day 7 in C57Bl/6N mice administered either vehicle or 527
PD325901 prior to daily SA sessions. An independent samples t-test revealed that animals 528
administered PD325901 demonstrated a significant decrease in the number of pERK1/2-529
positive cells in the ventral striatum relative to vehicle controls [t(8) = 3.8, p = .005]. Figure 530
8D shows the mean number of pERK1/2-positive cells (± SEM) in the dorsal striatum on day 531
7 in C57Bl/6N mice administered either vehicle or PD325901 prior to daily SA sessions. An 532
independent samples t-test revealed that animals administered PD325901 demonstrated a 533
significant decrease in the number of pERK1/2-positive cells in the dorsal striatum relative to 534
vehicle controls [t(4.0) = 5.6, p = .005]. Figure 8E shows representative slices of pERK1/2-535
positive cells from the ventral and dorsal striatum of C57Bl6N mice administered vehicle or 536
PD325901. PD325901 treatment also resulted in an increase in the number of cocaine 537
infusions in these mice (data not shown); a two-way ANOVA (treatment x day) revealed a 538
significant main effect of treatment [F(1,8) = 5.4, p = .048], but no significant effect of day 539
[F(1,8) = 2.8, p = .136] or treatment x day interaction [F < 1] for days 1-6, and no difference 540
on the shortened day 7 [independent samples t-test: t(8) = 1.9, p = .090].541
542
Vehicle- and PD325901-administered mice differed in cocaine intake following intra-NAc 543
administration. Figure 9A shows the mean (± SEM) number of cocaine infusions received 544
during 9d of cocaine SA, with intra-NAc administration of PD325901 or vehicle conducted 545
30 min prior to the session on day 7. A two-way ANOVA (treatment x day) of days 1-6 546
revealed no difference between PD325901 or vehicle groups prior to intra-NAc 547
microinjections [Fs < 1 except day: F(5,85) = 13.2, p < .0005]. Independent samples t-tests of 548
the number of cocaine infusions received on days 7-9 indicate that PD325901-injected mice 549
showed a decrease in cocaine intake relative to vehicle-treated mice on day 8 [t(17) = 2.8, p = 550
.012], but not day 7 or 9 [day 7: t(17) = 1.1, p =  .290; day 9: t(17) = 1.3, p = .228]. Figure 9B 551
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shows a representative image from a cannula-mounted mouse showing dye injected into the 552
cannula tract in the NAc. 553
554
Vehicle- and PD325901-administered mice did not differ in cocaine intake following intra-DS 555
administration. Figure 9C shows the mean (± SEM) number of cocaine infusions received 556
during 9d of cocaine SA, with intra-DS administration of PD325901 or vehicle conducted 30 557
min prior to the session on day 7. A two-way ANOVA (treatment x day) of days 1-6 revealed 558
no difference between PD325901 and vehicle groups prior to intra-DS microinjections [Fs < 559
1]. Independent samples t-tests of the number of cocaine infusions received on days 7-9 560
indicate that PD325901- and vehicle-treated mice showed no difference in cocaine intake on 561
any of the three days [day 7: t(11) = 0.1, p = .891; day 8: t(11) = 1.3, p = .237; day 9: t(11) = 562
0.7, p = .525]. Figure 9d shows a representative image from a cannula-mounted mouse 563
showing dye injected into the cannula tract in the DS.564
565
These data confirm somewhat our previous findings in RasGRF2 KO mice and LV-566
RasGRF2-shRNA mice. Consistent with the RasGRF2 KO line, peripheral PD325901 567
resulted in an increase in cocaine SA, suggesting that general, or systemic, alterations in Ras-568
ERK signaling may result in a decrement in cocaine reward that is overcome by increasing 569
cocaine intake. Consistent with our findings with LV-RasGRF2-shRNA in mice, PD325901 570
administered into the NAcc reduced cocaine intake, albeit temporarily, suggesting that 571
focused Ras-ERK inhibition may decrease cocaine reward.572
573
574
575
576
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Discussion 577
578
Here we sought to extend the understanding of the role of the Ras-ERK pathway in general, 579
and RasGRF1 and RasGRF2 more specifically, in drug-mediated behaviors using operant 580
responding for cocaine in mice. Cocaine SA resulted in an increase in pERK1/2- and pAcH3-581
positive cells in both the ventral and dorsal striatum relative to controls. RasGRF2 KO mice 582
demonstrated an increase in cocaine SA, while RasGRF1 KO in mice had no effect, 583
suggesting that RasGRF2 is more relevant to the primary reinforcing properties of cocaine 584
than RasGRF1. Increases in pERK1/2- and pAcH3-positive cells in the ventral and dorsal 585
striatum resulting from cocaine SA in WT mice were absent in RasGRF2 KO mice, 586
suggesting an important role of the Ras-ERK signaling cascade in cocaine reinforcement 587
during cocaine SA. Finally, microinjection of LV-RasGRF2-shRNA, but not LV-RasGRF1-588
shRNA, into both the NAc and DS reduced cocaine intake during SA relative to LV-589
scrambled-shRNA controls, although this effect was opposite to that seen in RasGRF2 KO 590
mice. Importantly, daily pre-session peripheral administration of the MEK inhibitor 591
PD325901 replicated both the behavioral and molecular effects demonstrated in RasGRF2 592
KO mice, increasing cocaine intake and decreasing pERK1/2 expression during SA.  In 593
contrast, intra-NAc administration of PD325901 resulted in a similar decrease in cocaine 594
intake to that demonstrated following LV-RasGRF2-shRNA administration, albeit only 595
temporarily, while intra-DS PD325901 had no effect. These data suggest that RasGRF2 plays 596
an important role in cocaine reward in mice that can be differentiated on the global and more 597
focal levels.598
599
Our demonstration of an increase in the number of pERK1/2-positive cells in both the dorsal 600
and ventral striatum in response to cocaine relative to controls is consistent with other studies 601
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demonstrating pERK activation following acute and repeated peripheral injections of cocaine 602
(Valjent et al., 2004; Papale et al., 2016). Furthermore, the increase in the number of pAcH3-603
positive cells in both the ventral and dorsal striatum is consistent with increases in the 604
expression of pERK1/2. Histone H3 is a nuclear ERK substrate activated by mitogen and 605
stress-activated protein kinase 1 (MSK1) that has been linked to the transcriptional activation 606
of IEGs such as c-fos (Thomson et al., 1999; Clayton and Mahadevan, 2003), which have 607
been demonstrated to be critical to the enduring plasticity associated with drugs of 608
abuse (Berke and Hyman, 2000; Chandra and Lobo, 2017). Following activation in the 609
cytoplasm, pERK translocates to the nucleus, where it activates MSK1, which subsequently 610
phosphorylates Histone H3 (Brami-Cherrier et al., 2009). The findings of increased pERK1/2 611
and pAcH3 are consistent with a role for the Ras-ERK pathway in the striatum in cocaine SA.612
613
Cocaine SA in RasGRF2 KO mice resulted in an increase in SA relative to WT mice. In 614
contrast, cocaine SA was not affected in RasGRF1 KO mice, suggesting dissociation between 615
the actions of RasGRF1 and RasGRF2 on cocaine reward. Previous work has demonstrated 616
both impaired conditioned sensitization and CPP in response to cocaine in RasGRF1 KO mice 617
relative to controls (Fasano et al., 2009). These data suggest that RasGRF2 is more relevant 618
for cocaine reward, while RasGRF1 may mediate conditioned responding following the 619
learning of associations between cocaine and cocaine-associated cues and environments.620
621
The increase in cocaine SA in RasGRF2 KO mice likely reflects a decrease in the magnitude 622
of the cocaine reinforcer, requiring an increase in cocaine intake to achieve a similar putative 623
subjective effect, similar to that demonstrated following a reduction in the dose of cocaine 624
(e.g., Thomsen and Caine, 2006). This effect is similar to that seen with peripheral injections 625
of dopamine D1-receptor (D1R) antagonists. The D1R antagonist SCH-23390 has been 626
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consistently demonstrated to increase cocaine SA when administered systemically (Haile and 627
Kosten, 2001; Caine et al., 2007) in rodents. Previous research has specifically implicated628
D1R-mediated signaling (Valjent et al., 2000; Zhang et al., 2004; Bertran-Gonzalez et al., 629
2008)-- in concert with NMDA receptor activation (Jiao et al., 2007; Ren et al., 2010)-- via630
subsequent Ras-ERK activation as a critical factor in the regulation of cocaine-dependent 631
synaptic plasticity in the striatum (Girault et al., 2007; Cerovic et al., 2013). In addition to a 632
clear postsynaptic role for Ras-ERK signaling resulting from dopaminergic activity, RasGRF2 633
has also been identified as part of the proteome of the dopamine transporter (Maiya et al., 634
2007), suggesting a potential presynaptic role for RasGRF2, such as influencing DA release 635
(Bloch-Shilderman et al., 2001).636
637
Our pERK1/2 data in the RasGRF2 line confirm the likelihood that RasGRF2 mediates its 638
effects via the Ras-ERK pathway.  RasGRF2 KO mice did not show the increase in pERK1/2-639
positive cells in the ventral and dorsal striatum demonstrated in WT littermates and in our first 640
experiment, a likely mechanistic explanation for the increase in SA demonstrated in RasGRF2 641
KO mice. The increased pAcH3 outlined in the first experiment was also replicated in 642
RasGRF2 WT controls, but absent in RasGRF2 KO mice. These findings further implicate 643
this ERK substrate in cocaine SA in mice. Previous studies have demonstrated that an acute 644
injection of cocaine resulted in an increase in pAcH3 (Brami-Cherrier et al., 2005; Bertran-645
Gonzalez et al., 2008), an effect not present in MSK1 KO mice (Brami-Cherrier et al., 2005)--646
which also lacked a c-Fos response-- and impaired when preceded by the MEK inhibitor 647
PD325901 (Papale et al., 2016). Our findings suggest that the inhibition of a cocaine-induced 648
increase in pAcH3 is at least in part mediated through the Ras-ERK pathway via RasGRF2.649
650
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In contrast to our findings in RasGRF2 KO mice, cocaine intake decreased following 651
microinjection of LV-RasGRF2-shRNA into the NAc relative to LV-scrambled-shRNA. It is 652
not entirely clear why the response to cocaine differed in these animals, but may result from a 653
focal knockdown of RasGRF2, in contrast to the global disruption of RasGRF2 in KO 654
animals. In fact, it has been previously hypothesized that the knockout of RasGRF2 in mice 655
resulted in a reduced excitability of VTA DA neurons and subsequent generalized disruption 656
of dopaminergic signaling, which caused a reduction in alcohol consumption in RasGRF2 KO 657
mice relative to controls (Stacey et al., 2012). This hypothesis is consistent with the alteration 658
in basal extracellular DA levels demonstrated in RasGRF2 KO mice (Stacey et al., 2012). In 659
terms of the studies reported here, a disruption in dopaminergic signaling may have resulted 660
in a minor decrease in cocaine reward that was overcome by increased cocaine intake. In 661
contrast, knockdown of RasGRF2 in the NAc likely resulted in a focused, disruptive effect in 662
a brain region that specifically mediates putative cocaine reward (Wise and Bozarth, 1985; 663
Koob and Volkow, 2010). For example, previous studies have demonstrated that minor 664
decreases in cocaine reward result in compensatory increases in cocaine intake, while further 665
decreases result in a reduction of intake (De Wit and Wise, 1977; Ettenberg et al., 1982; Caine 666
and Koob, 1994). These divergent findings may implicate brain areas outside of the striatum 667
in the effects of the RasGRF2 KO on cocaine reward. As already mentioned, RasGRF2 may 668
play an important role on DAT-containing neurons (Bloch-Shilderman et al., 2001). 669
Nonetheless, our data confirm that RasGRF2 is involved in cocaine reward during SA. In 670
contrast, LV-RasGRF1-shRNA administration had no effect on cocaine SA relative to LV-671
scrambled-shRNA controls, consistent with our findings in RasGRF1 KO mice.672
673
Interestingly, microinjection of LV-RasGRF2-shRNA into the DS also resulted in a decrease 674
in cocaine intake. Beyond its well-known role in the control of habitual behavior following 675
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extensive drug-taking (Everitt and Robbins, 2005; Pierce and Vanderschuren, 2010), some 676
previous research has also indicated a role for the DS in the acute reinforcing properties of 677
cocaine. For example, the magnitude of the dopaminergic response to self-administered 678
cocaine in drug-naïve rats was shown to be similar in the NAc and DS (D'Souza and 679
Duvauchelle, 2006).  In addition, Veeneman et al. (2012) demonstrated that the DA receptor 680
antagonist α-flupenthixol administered into the dorsolateral striatum (DLS) altered cocaine 681
SA in rats even after limited exposure (see also Kantak et al., 2002), and disconnection 682
studies between the NAc shell and DLS with α-flupenthixol demonstrated that these serial 683
connections mediate cocaine reinforcement during early cocaine exposure (Veeneman et al., 684
2015). A role for the DS in cocaine reinforcement is consistent with our molecular results 685
above, in which cocaine SA increased pERK activation in the DS in addition to the VS, 686
effects impaired in KO mice. Further studies will need to clarify whether this effect of 687
RasGRF2 inhibition is due to a serial connection between the VS and DS or results from 688
another as yet unspecified role of the DS in cocaine SA.689
690
Daily SA sessions preceded by administration of the MEK inhibitor PD325901 increased 691
cocaine intake while simultaneously decreasing pERK1/2 levels in the ventral and dorsal 692
striatum. These findings replicated those seen in RasGRF2 KO mice, suggesting that693
RasGRF2 exerts its effects via the Ras-ERK signaling cascade and confirming the likelihood 694
that a global inhibition of Ras-ERK signaling may result in a loss in cocaine reward that is 695
overcome by a compensatory increased intake.  In terms of cocaine, few, if any, studies have 696
demonstrated alterations in cocaine intake specifically during SA resulting from the inhibition 697
of activity of components of the Ras-ERK signaling pathway, such as impairment of MEK 698
(but see Miszkiel et al., 2014). However, numerous previous studies have demonstrated the 699
involvement of MEK, and the subsequent activity of ERK, in other cocaine-related behaviors, 700
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such as CPP (e.g., Valjent et al., 2000; Miller and Marshall, 2005; Papale et al., 2016), which 701
support an inhibitory role of Ras-ERK signaling blockade on cocaine reward. For example, 702
we previously demonstrated that PD325901 administered prior to a test for cocaine 703
conditioned place preference (CPP) resulted in the long-term inhibition of CPP and a 704
complete attenuation of an acute cocaine-induced increase in pERK1/2 in the ventral striatum705
(Papale et al., 2016). SL327, like PD325901 one of only a few available blood-brain barrier 706
penetrating MEK inhibitors, was also shown to increase alcohol SA in mice when 707
administered prior to daily sessions (Faccidomo et al., 2009) and was interpreted as a 708
compensatory increase in responding due to a decrease in alcohol reward. In addition, 709
RasGRF2 KO mice have previously been shown to demonstrate a loss in alcohol-induced 710
dopamine increase in the NAc and dorsal striatum (Stacey et al. 2012), suggesting a reduction 711
in alcohol reinforcement and consistent with a modulatory role of the Ras-ERK pathway in 712
drug-mediated behaviors.713
714
The site-specific administration of PD325901 into the NAc, but not DS, resulted in a decrease 715
in cocaine intake. PD administered into the NAc failed to have an immediate effect, but 716
during the next session on day 8 resulted in a temporary decrease in cocaine intake that was 717
no longer significant on day 9. A lack of effect on day 7 is not surprising given that the 718
relatively stressful injection procedures likely masked any potential differences between the 719
groups. The decrease in intake the following day is consistent with the pharmacokinetics of 720
PD325901, which showed 50% inhibition of pERK at approximately 24h in rodent brain at 721
the dose used in the current study (Iverson et al., 2009). Furthermore, this effect is consistent 722
with the decrease in cocaine intake following LV-RasGRF2-shRNA, again suggesting that a 723
NAc-specific inhibition of Ras-ERK signaling resulted in an impairment in cocaine SA.724
That PD325901 had no effect on cocaine intake may be surprising given that LV-RasGRF2-725
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shRNA in the DS resulted in a reduction in intake similar to that seen with LV-RasGRF2-726
shRNA in the NAc. As noted above, several studies have suggested a role for the DS in 727
cocaine reward during early exposure, and RasGRF2 knockdown prior to cocaine SA in mice 728
may have inhibited the acquisition of SA, while MEK inhibition at a single administration 729
after several days of SA failed to affect the maintenance of cocaine SA. However, further 730
disentanglement of the specific role of RasGRF2 in the DS during cocaine SA is required.731
732
In summary, we used a combination of molecular, pharmacological, and lentiviral techniques 733
to demonstrate that RasGRF2, but not RasGRF1, is involved in cocaine reinforcement 734
associated with operant SA. These studies further implicate the role of the Ras-ERK pathway 735
in the effects of drugs of abuse and indicate that RasGRF2 may be a risk factor in the cocaine 736
use that may ultimately lead to dependence in humans.737
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964
965
Figure 1.  Cocaine SA increased pERK1/2 and pAcH3 in C57Bl6/N mice.  Cocaine (n = 5) 966
SA resulted in an increase in the number of pERK1/2-positive cells relative to saline controls967
(n = 6) in both the (A) ventral and (B) dorsal striatum. Data represent mean number of 968
pERK1/2-positive cells (± SEM) in each condition. (C) Representative slices showing pERK-969
positive cells from the ventral and dorsal striatum of C57Bl6N mice that underwent cocaine 970
or saline SA. Cocaine SA resulted in an increase in the number of pAcH3-positive cells 971
relative to saline controls in both the (D) ventral and (E) dorsal striatum. (F) Representative 972
slices showing pAcH3-positive cells from the ventral and dorsal striatum of C57Bl6N mice 973
that underwent cocaine or saline SA. Mice were sacrificed for immunohistochemistry on day 974
7 of SA, 30 min following the 1st injection of cocaine.  *p < .05; **p < .005   975
976
Figure 2.  Cocaine SA in RasGRF1 and RasGRF2 KO mice and WT controls.  (A) RasGRF1 977
KO mice (n = 11) did not differ in lever responding relative to WT controls (n = 10). Data 978
represent mean number of presses (± SEM) on the active and inactive levers during 7 daily 1 979
hr sessions of cocaine SA (0.50 mg/kg/14 µl infusion).  (B) RasGRF1 KO mice did not differ 980
in the number of cocaine reinforcers achieved relative to WT controls.  Data represent mean 981
number of cocaine reinforcers (± SEM) achieved during 7 daily 1 hr sessions of cocaine SA 982
(0.50 mg/kg/14 µl infusion). (C) RasGRF2 KO mice (n = 19) demonstrated an increase in 983
responding on the cocaine-associated lever relative to WT controls (n = 14).  Data represent 984
mean number of presses (± SEM) on the active and inactive levers during 7 daily 1 hr sessions 985
of cocaine SA (0.50 mg/kg/14 µl infusion).  (D) RasGRF2 KO mice demonstrated an increase 986
in the number of cocaine reinforcers achieved relative to WT controls.  Data represent mean 987
41 
number of cocaine reinforcers (± SEM) achieved during 7 daily 1 hr sessions of cocaine SA 988
(0.50 mg/kg/14 µl infusion). #p < .05, main effect of genotype; **p < .005989
990
Figure 3. Cocaine SA resulted in an increase in pERK1/2 and pAcH3 in WT, but not KO, 991
mice of the RasGRF2 line. Cocaine SA resulted in an increase in the number of pERK1/2-992
positive cells relative to saline controls in both the (A) ventral and (B) dorsal striatum in WT 993
mice (cocaine, n = 5; saline, n = 5), an effect not present in RasGRF2 KO mice (cocaine, n = 994
5; saline, n = 5). Data represent mean number of pERK1/2-positive cells (± SEM) in each 995
condition. (C) Representative slices showing pERK-positive cells from the ventral and dorsal 996
striatum of RasGRF2 KO mice and WT controls that underwent cocaine or saline SA. 997
Cocaine SA resulted in an increase in the number of pAcH3-positive cells relative to saline 998
controls in both the (D) ventral and (E) dorsal striatum in WT mice, an effect not present in 999
RasGRF2 KO mice. (F) Representative slices showing pAcH3-positive cells from the ventral 1000
and dorsal striatum of RasGRF2 KO mice and WT controls that underwent cocaine or saline 1001
SA. Mice were sacrificed for immunohistochemistry on day 7 of SA, 30 min following the 1st1002
injection of cocaine.  *p < .051003
1004
Figure 4.  LV-RasGRF2-shRNA microinjected into the NAc decreased cocaine intake. (A) 1005
Representative images of viral eGFP expression in the NAc following microinjections of 1006
RasGRF2-shRNA (left) or LV-scrambled-shRNA (right) using fluorescent microscopy. (B) 1007
Representative images of viral eGFP expression in the NAc following microinjections of 1008
RasGRF1-shRNA (left) or LV-scrambled-shRNA (right) using DAB staining. (C) Mice 1009
microinjected with LV-RasGRF2-shRNA (n = 9) and LV-scrambled-shRNA (n = 11) did not 1010
differ significantly in lever responding. Data represent mean number of presses (± SEM) on 1011
the active and inactive levers during 7 daily 1 hr sessions of cocaine SA (0.50 mg/kg/14 µl 1012
42 
infusion). (D) The number of cocaine reinforcers achieved differed significantly between the 1013
groups across daily sessions, with the LV-RasGRF2-shRNA group earning less reinforcers 1014
than the LV-scrambled-shRNA group. Data represent mean number of reinforcers (± SEM) 1015
achieved during 7 daily 1 hr cocaine SA sessions (0.50 mg/kg/14 µl infusion). *p < .05, main 1016
effect of treatment  1017
1018
Figure 5.  LV-RasGRF1-shRNA microinjected into the NAc had no effect on cocaine SA. (A) 1019
Representative images of viral eGFP expression in the NAc following microinjections of 1020
RasGRF1-shRNA (left) or LV-scrambled-shRNA (right) using fluorescent microscopy. (B) 1021
Representative images of viral eGFP expression in the NAc following microinjections of 1022
RasGRF1-shRNA (left) or LV-scrambled-shRNA (right) using DAB staining. (C) Mice 1023
microinjected with LV-RasGRF1-shRNA (n = 12) and LV-scrambled-shRNA (n = 13) did not 1024
differ significantly in lever responding. Data represent mean number of presses (± SEM) on 1025
the active and inactive levers during 7 daily 1 hr sessions of cocaine SA (0.50 mg/kg/14 µl 1026
infusion). (D) The number of cocaine reinforcers achieved did not differ significantly between 1027
the groups across daily sessions. Data represent mean number of reinforcers (± SEM) 1028
achieved during 7 daily 1 hr cocaine SA sessions (0.50 mg/kg/14 µl infusion). 1029
1030
Figure 6.  LV-RasGRF2-shRNA microinjected into the DS decreased cocaine intake. (A) 1031
Representative images of viral eGFP expression in the DS following microinjections of 1032
RasGRF2-shRNA (left) or LV-scrambled-shRNA (right) using fluorescent microscopy. (B) 1033
Representative images of viral eGFP expression in the DS following microinjections of 1034
RasGRF2-shRNA (left) or LV-scrambled-shRNA (right) using DAB staining. (C) Mice 1035
microinjected with LV-RasGRF2-shRNA (n = 9) and LV-scrambled-shRNA (n = 6) did not 1036
differ significantly in lever responding. Data represent mean number of presses (± SEM) on 1037
43 
the active and inactive levers during 7 daily 1 hr sessions of cocaine SA (0.50 mg/kg/14 µl 1038
infusion). (D) The number of cocaine reinforcers achieved differed significantly between the 1039
groups across daily sessions, with the LV-RasGRF2-shRNA group earning less reinforcers 1040
than the LV-scrambled-shRNA group. Data represent mean number of reinforcers (± SEM) 1041
achieved during 7 daily 1 hr cocaine SA sessions (0.50 mg/kg/14 µl infusion). *p < .05, main 1042
effect of treatment  1043
1044
Figure 7.  LV-RasGRF2-shRNA decreased pERK.  LV-RasGRF2-shRNA (n = 9) resulted in 1045
a decrease in the number of pERK-positive cells as compared to LV-scrambled-shRNA (n = 1046
6) in the dorsal striatum in mice sacrificed immediately following the final cocaine SA 1047
session on day 7. Data represent mean number of pERK1/2-positive cells (± SEM) in each 1048
condition, with representative slices showing pERK-positive cells from the dorsal striatum of 1049
LV-RasGRF2-shRNA and LV-scrambled-shRNA below.  ***p < .0005   1050
1051
Figure 8.  PD325901 administered IP increased cocaine intake and decreased pERK. (A) Mice 1052
treated with IP vehicle (VEH; n = 9) or PD325901 (PD, 10 mg/kg; n = 11) prior to daily 1053
cocaine SA sessions did not differ significantly in lever responding. Data represent mean 1054
number of presses (± SEM) on the active and inactive levers during 7 daily 1 hr sessions of 1055
cocaine SA (0.50 mg/kg/14 µl infusion). (B) The number of cocaine reinforcers achieved 1056
differed significantly between the groups across daily sessions, with the PD group earning 1057
more reinforcers than the VEH group. Data represent mean number of reinforcers (± SEM) 1058
achieved during 7 daily 1 hr cocaine SA sessions (0.50 mg/kg/14 µl infusion). PD325901 (n = 1059
5) decreased the number of pERK1/2-positive cells relative to vehicle (n = 5) in both the (C) 1060
ventral and (D) dorsal striatum following pretreatment prior to 7 daily cocaine SA sessions. 1061
Data represent mean number of pERK1/2-positive cells (± SEM) in each condition. (E) 1062
44 
Representative slices showing pERK-positive cells from the ventral and dorsal striatum of 1063
C57Bl6N mice that received vehicle or PD325901. Mice were sacrificed for 1064
immunohistochemistry on day 7 of SA, 30 min following the 1st injection of cocaine. **p < 1065
.005, main effect of treatment; ##p = .0051066
1067
Figure 9.  Intra-NAc, but not intra-DS, PD325901 decreased cocaine intake. (A) The number 1068
of cocaine reinforcers achieved differed between groups administered vehicle (VEH; n = 10) 1069
or PD325901 (PD; n = 9) into the NAc only on day 8, with the PD325901 group earning less 1070
reinforcers than the vehicle group. Data represent mean number of reinforcers (± SEM) 1071
achieved during 9 daily 1 hr cocaine SA sessions (0.50 mg/kg/14 µl infusion). PD325901 (5 1072
ng/0.5 µl /side) or vehicle was administered into the NAc 30 minutes prior to the day 7 SA 1073
session; inset shows a representative image from a cannula-mounted mouse showing dye 1074
injected into the cannula tract in the NAc (black arrows denote location of catheter tip). (B) 1075
The number of cocaine reinforcers achieved differed between groups administered vehicle 1076
(VEH; n = 6) or PD325901 (PD; n = 7) into the DS only on day 8, with the PD325901 group 1077
earning less reinforcers than the vehicle group. Data represent mean number of reinforcers (± 1078
SEM) achieved during 9 daily 1 hr cocaine SA sessions (0.50 mg/kg/14 µl infusion).1079
PD325901 (5 ng/0.5 µl /side) or vehicle was administered into the DS 30 minutes prior to the 1080
day 7 SA session; inset shows a representative image from a cannula-mounted mouse 1081
showing dye injected into the cannula tract in the DS (black arrows denote location of catheter 1082
tip). *p < .05 1083
1084
1085









